PHAT (PHAT) Stock Analysis
Verdict: HOLD
VOQUEZNA commercial expansion drives 110% revenue growth, but sub-10 month cash runway and $211.8M debt force severe dilution risk.
Investment score: 41/100
Is PHAT Stock Worth Reviewing? AI Model Thesis
The model score of 41/100 falls in the HOLD range. The central thesis and factor breakdown explain the assessment.
Peers
| Peer | P/E | P/B | P/S | EV/EBITDA | ROIC % | Net margin % |
|---|---|---|---|---|---|---|
| LXRX | -11.93 | 4.50 | 19.23 | -15.61 | — | -1.47 |
| ACRS | -8.88 | 5.90 | 87.51 | -9.32 | — | -9.21 |
| COLL | 14.73 | 2.34 | 0.90 | 2.49 | — | 0.06 |
| CRMD | 3.26 | 1.34 | 1.33 | 2.02 | — | 0.40 |
Should You Buy or Sell PHAT Stock? Model Reasoning
The model score of 41/100 falls in the HOLD range. The central thesis and factor breakdown explain the assessment.
PHAT Fair Value & Price Target — AI Valuation
- Model Assumptions: ["Voquezna revenue accelerates toward consensus expectations of $500M in FY2027 and $680M in FY2028.","Gross margins remain structurally protected above 80% (currently 82.92%).","Management successfully bridges the 9.4-month cash runway via non-dilutive credit or manageable equity financing."]
PHAT Risk & Opportunity Analysis
Key Investment Risks
- Imminent Cash Runway Wall — Cash reserves of $129.97M cover only ~9.3 months of annual free cash flow burn (-$166.78M), triggering dilutive share issuance before Q3 2026.
- Balance Sheet Insolvency and Debt Overhang — Total liabilities ($697.32M) exceed assets ($259.15M) by $438.17M, with $211.80M in debt restricting strategic options.
- Severe Technical Breakdown — Shares dropped 35.89% over the past 90 days to $7.30, leaving the stock vulnerable to breaking below support at the 52-week low of $6.91.
- Absence of Insider Support — Zero open-market insider purchases were executed in 2026 despite the stock falling 60.1% below its 52-week high of $18.31.
Growth Opportunities & Upside Drivers
- VOQUEZNA Commercial Scalability — 2025 annual revenue increased 110.16% YoY to $175.11M with gross margins reaching 82.92%, demonstrating strong commercial reception in erosive GERD.
- Consensus Path to Profitability — Analyst consensus estimates forecast revenue reaching $500.00M in 2027 with EPS swinging positive to $0.78, expanding to $2.14 EPS on $680.00M revenue by 2028-12-31.
- Wall Street Target Premium — 15 of 17 analysts assign Strong Buy or Buy recommendations, maintaining an average price target of $17.60 (+141.1% upside from $7.30).
- Consistent Earnings Beats — PHAT beat consensus EPS expectations in 3 of the last 4 quarters, including a $0.05 beat in 2026 Q2 (-$0.21 vs -$0.26 expected).
PHAT Action Plan — Entry, Exit and Stop Loss from the Model View
moderate
aggressive
conservative
Frequently Asked Questions About PHAT (PHAT)
Is PHAT stock a good investment?
The cached TradeMates AI model rates PHAT as HOLD with an investment score of 41/100. The model score of 41/100 falls in the HOLD range. The central thesis and factor breakdown explain the assessment. This is algorithmic model output, not personal investment advice.
Does PHAT pay a dividend?
The cached stock data on this page does not show a positive dividend yield for PHAT. Dividend status can change, so verify the latest company filings before relying on income assumptions.
What does PHAT stock do?
Commercial-stage biopharmaceutical company focused on developing and commercializing vonoprazan (Voquezna), a novel potassium-competitive acid blocker (P-CAB) for acid-related gastrointestinal disorders.
What is PHAT stock's price target?
This cached page does not contain a precise model fair value for PHAT.
Is PHAT stock a buy?
The TradeMates model verdict for PHAT is HOLD with an investment score of 41/100. Treat this as a model signal to review, not a personal buy recommendation.
Is PHAT a good dividend stock?
PHAT is not presented as a dividend idea on this cached TradeMates page because no positive dividend yield is available in the cached data.